Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acumen Pharmaceuticals, Inc.

1.20
+0.130012.15%
Post-market: 1.200.00000.00%19:56 EDT
Volume:383.45K
Turnover:432.51K
Market Cap:72.69M
PE:-0.62
High:1.21
Open:1.09
Low:1.06
Close:1.07
Loading ...

Acumen Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
06 Jun

Acumen Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Acumen Pharmaceuticals Inc. Unveils Presentation on Sabirnetug Antibody Targeting Toxic Amyloid Beta Oligomers for Early Alzheimer's Treatment

Reuters
·
13 May

Acumen Pharmaceuticals Q1 GAAP EPS $(0.48) Beats $(0.54) Estimate

Benzinga
·
13 May

BRIEF-Acumen Pharmaceuticals, Inc. Q1 Income From Operations USD -30.37 Million

Reuters
·
13 May

Acumen Pharmaceuticals Reports Q1 2025 Net Loss of $28.8 Million, Doubling from Previous Year

Reuters
·
13 May

Acumen Pharmaceuticals, Inc. Q1 Operating Expenses USD 30.37 Million

THOMSON REUTERS
·
13 May

Press Release: Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

Dow Jones
·
13 May

Acumen Pharmaceuticals Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
10 May

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

THOMSON REUTERS
·
01 Apr

Acumen Pharmaceuticals’ Promising Alzheimer’s Strategy Earns Buy Rating with Revised Price Target

TIPRANKS
·
29 Mar

Acumen Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Mar

UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating

MT Newswires Live
·
28 Mar

Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ...

GuruFocus.com
·
28 Mar

Q4 2024 Acumen Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Mar

Acumen Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

Acumen Pharmaceuticals FY 2024 EPS $(1.71) Misses $(1.55) Estimate

Benzinga
·
27 Mar

BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -114.017 Million

Reuters
·
27 Mar

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

THOMSON REUTERS
·
27 Mar

Acumen Pharmaceuticals, Inc. FY Net Income USD -102.329 Million

THOMSON REUTERS
·
27 Mar